Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ADIL

ADIL - Adial Pharmaceuticals Inc Stock Price, Fair Value and News

0.84USD-0.10 (-10.64%)Market Closed
Watchlist

Market Summary

USD0.84-0.10
Market Closed
-10.64%

ADIL Stock Price

View Fullscreen

ADIL RSI Chart

ADIL Valuation

Market Cap

1.1M

Price/Earnings (Trailing)

-0.19

EV/EBITDA

-0.08

Price/Free Cashflow

-0.16

MarketCap/EBT

-0.11

ADIL Price/Sales (Trailing)

ADIL Profitability

Return on Equity

-259.47%

Return on Assets

-211.68%

Free Cashflow Yield

-640.68%

ADIL Fundamentals

ADIL Earnings

Earnings (TTM)

-6.1M

Earnings Growth (Yr)

55.46%

Earnings Growth (Qtr)

-227.32%

Breaking Down ADIL Revenue

Last 7 days

-0.9%

Last 30 days

-20.7%

Last 90 days

-45.2%

Trailing 12 Months

-86.9%

How does ADIL drawdown profile look like?

ADIL Financial Health

Current Ratio

2.15

ADIL Investor Care

Shares Dilution (1Y)

13.39%

Diluted EPS (TTM)

-5.64

Tracking the Latest Insider Buys and Sells of Adial Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 29, 2023
schuyler kevin
bought
1,918
2.74
700
-
May 23, 2023
truluck joseph
acquired
-
-
157,500
chief financial officer
May 23, 2023
stilley william b. iii
acquired
-
-
240,800
-
May 23, 2023
claiborne cary j
acquired
-
-
420,000
chief executive officer
Dec 30, 2022
stilley william b. iii
back to issuer
-
-
-166,667
-
Sep 20, 2022
claiborne cary j
acquired
31,515
0.4202
75,000
chief executive officer
Sep 19, 2022
claiborne cary j
acquired
10,735
0.4294
25,000
chief executive officer
Aug 18, 2022
claiborne cary j
acquired
-
-
1,000,000
chief executive officer
Feb 23, 2022
stilley william b. iii
acquired
-
-
250,000
chief executive officer
Dec 30, 2021
newman james w. jr.
bought
13,600
2.72
5,000
-

1–10 of 36

Which funds bought or sold ADIL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
new
-
27,508
27,508
-%
Feb 14, 2024
Royal Bank of Canada
unchanged
-
-
-
-%
Feb 13, 2024
MORGAN STANLEY
reduced
-57.14
-41.00
17.00
-%
Feb 13, 2024
Qube Research & Technologies Ltd
unchanged
-
-6.00
15.00
-%
Feb 13, 2024
ARMISTICE CAPITAL, LLC
new
-
295,740
295,740
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
new
-
7,875
7,875
-%
Feb 13, 2024
BlackRock Inc.
unchanged
-
-7,027
14,209
-%
Feb 13, 2024
RENAISSANCE TECHNOLOGIES LLC
new
-
43,000
43,000
-%
Feb 12, 2024
JPMORGAN CHASE & CO
new
-
4,650
4,650
-%
Feb 12, 2024
OSAIC HOLDINGS, INC.
added
0.81
-557
1,153
-%

1–10 of 18

Are Funds Buying or Selling ADIL?

Are funds buying ADIL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ADIL
No. of Funds

Unveiling Adial Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
9.99%
166,972
SC 13G
Feb 14, 2022
peikin mark howard
4.4%
904,444
SC 13G/A
Aug 18, 2021
peikin mark howard
6.67%
1,346,741
SC 13G/A
Aug 13, 2021
peikin mark howard
5.52%
1,120,241
SC 13G
Aug 13, 2021
stilley william b. iii
9.38%
2,005,752
SC 13D/A
Feb 16, 2021
armistice capital, llc
4.5%
712,500
SC 13G/A
Feb 08, 2021
stilley william b. iii
11.1%
1,769,363
SC 13D/A
Dec 11, 2020
stilley william b. iii
9.97%
1,513,310
SC 13D/A
Jun 19, 2020
armistice capital, llc
5.0%
712,500
SC 13G
Jun 18, 2020
intracoastal capital, llc
3.4%
470,000
SC 13G

Recent SEC filings of Adial Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G
Major Ownership Report
Jan 25, 2024
424B5
Prospectus Filed
Jan 24, 2024
EFFECT
EFFECT
Jan 18, 2024
8-K
Current Report
Jan 16, 2024
8-K
Current Report
Jan 12, 2024
S-3
S-3
Dec 15, 2023
DEFA14A
DEFA14A
Dec 12, 2023
S-8
Employee Benefits Plan
Dec 08, 2023
DEF 14A
DEF 14A
Nov 29, 2023
8-K
Current Report

Peers (Alternatives to Adial Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.4B
9.1B
-16.59% -47.80%
-9.64
3.66
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
19.5B
1.8B
-23.99% -31.71%
-44.27
10.66
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.44
7.22
15.05% 75.21%
13.5B
3.7B
-7.62% -26.87%
22.67
3.67
8.87% 75.42%
MID-CAP
7.9B
272.9M
-2.06% 34.31%
-13.08
29.05
141.38% 4.43%
5.9B
107.9M
-3.85% 226.12%
-9.53
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.44
6.46
23.54% 31.53%
3.9B
223.4M
8.92% 47.81%
-19.25
17.39
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.18
15.02
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.56
4.2
81.69% -7.29%
472.8M
1.0B
-9.17% -57.89%
-0.86
0.45
-43.15% 58.48%
179.5M
4.9M
-14.18% -58.18%
-1.09
36.72
-57.57% 50.48%
120.1M
881.7K
289.54% 381.25%
-2.53
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Adial Pharmaceuticals Inc News

Latest updates
InvestorsObserver15 Feb 202401:36 pm

Adial Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-24.1%2,8673,7793,9025,7337,74210,92313,9647,47510,4468,0638,6255,4918,1789,4755,9417,6809,50710,68712,0604,6995,252
  Current Assets-44.5%1,1352,0472,9654,7806,7739,94012,9656,4627,9865,5906,1725,1368,1729,4695,9357,6739,50110,68112,0534,6935,245
    Cash Equivalents-74.1%3161,2182,3134,0025,7539,15712,6896,0627,1805,2105,6384,4017,3658,6244,9526,7778,53010,25411,3943,8694,817
  Net PPE---48.0050.0052.0054.0056.0058.0062.0062.0030.00----------
  Goodwill---249249249249249249131131131----------
Liabilities14.4%5284622,4622,4562,3332,9623,2563,9673,2463,2343,0081,505---------
  Current Liabilities14.4%5284621,7981,7911,3271,8672,1712,7221,9582,2132,0421,5051,093682390539777627329258323
Shareholder's Equity-29.5%2,3393,3171,4403,2765,4097,96110,7073,5087,2004,8295,6183,9867,0858,7935,5517,1418,73010,06111,7314,4414,929
  Retained Earnings-2.1%-66,877-65,492-66,580-63,674-60,807-57,698-53,850-50,943-45,112-40,794-36,353-31,519-28,050-24,714-22,903-20,626-18,568-16,852-14,718-12,035-10,766
  Additional Paid-In Capital0.6%69,21668,80967,99266,95066,19065,63464,53554,43052,29245,60541,95435,49135,12133,49428,44427,75727,28826,90326,43916,47015,689
Shares Outstanding1.7%1,2181,1981,1411,0671,0741,034926838715704691576546--------
Float------31,265---40,504---14,669---12,307---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations26.6%-1,390-1,894-2,298-1,750-3,403-3,534-2,496-2,373-3,529-3,203-2,843-2,614-2,208-985-1,825-1,752-1,724-1,140-1,721-1,103-991
  Share Based Compensation-63.6%2687384607345571,1009848841,1898431,3253706783955714693854642843003,468
Cashflow From Investing-350---------33.73-286*----------
Cashflow From Financing238984.5%13958*610--2.009,1241,2555,5002,8094,081-950--109*178*26*9,2461565,658

ADIL Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating Expenses:    
Research and development expenses$ 207,128$ 696,073$ 1,002,640$ 1,418,467
General and administrative expenses1,150,8081,858,5504,101,4666,843,513
Total Operating Expenses1,357,9362,554,6235,104,1068,261,980
Loss From Operations(1,357,936)(2,554,623)(5,104,106)(8,261,980)
Other Income (Expense)    
Interest income10,2363,47258,55415,517
Other income (expenses)(51,901)
Total other income (expense)10,2363,4726,65315,517
Loss Before Provision For Income Taxes(1,347,700)(2,551,151)(5,097,453)(8,246,463)
Provision for income taxes
Loss from Continuing Operations(1,347,700)(2,551,151)(5,097,453)(8,246,463)
Income (loss) from discontinued operations, net of taxes, including gain on disposal of $2,624,798(37,276)(558,199)1,894,445(1,618,258)
Net Loss$ (1,384,976)$ (3,109,350)$ (3,203,008)$ (9,864,721)
Loss per share from continuing operations, basic (in Dollars per share)$ (1.14)$ (2.48)$ (4.54)$ (8.31)
Income (Loss) per share from discontinued operations, basic (in Dollars per share)(0.03)(0.54)1.69(1.63)
Net loss per share, basic (in Dollars per share)$ (1.18)$ (3.02)$ (2.86)$ (9.94)
Weighted average shares, basic (in Shares)1,178,5371,028,9821,121,328992,156

ADIL Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 315,880$ 4,001,794
Purnovate sale payments receivable350,000
Prepaid expenses and other current assets469,606349,441
Current assets of discontinued operations428,700
Total Current Assets1,135,4864,779,935
Intangible assets, net4,0544,477
Equity method investment1,727,897
Assets of discontinued operations948,392
Total Assets2,867,4375,732,804
Current Liabilities:  
Accounts payable81,925276,410
Accrued expenses408,614963,327
Accrued expenses, related party30,000175,000
Other current liabilities7,64010,387
Current liabilities of discontinued operations365,742
Total Current Liabilities528,1791,790,866
Long-term Liabilities:  
Deferred tax liability1,690
Long-term liabilities of discontinued operations663,754
Total Liabilities528,1792,456,310
Commitments and contingencies – see Note 10
Stockholders’ Equity  
Preferred Stock, 5,000,000 shares authorized with a par value of $0.001 per share, 0 shares outstanding at September 30, 2023 and December 31, 2022
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 1,217,981 and 1,067,491 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively1,2181,067
Additional paid in capital69,215,57966,949,958
Accumulated deficit(66,877,539)(63,674,531)
Total Stockholders’ Equity2,339,2583,276,494
Total Liabilities and Stockholders’ Equity$ 2,867,437$ 5,732,804
ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
 CEO
 WEBSITEwww.adialpharma.com
 EMPLOYEES16

Adial Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Adial Pharmaceuticals Inc? What does ADIL stand for in stocks?

ADIL is the stock ticker symbol of Adial Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adial Pharmaceuticals Inc (ADIL)?

As of Wed Feb 21 2024, market cap of Adial Pharmaceuticals Inc is 1.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADIL stock?

You can check ADIL's fair value in chart for subscribers.

What is the fair value of ADIL stock?

You can check ADIL's fair value in chart for subscribers. The fair value of Adial Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adial Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADIL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adial Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ADIL is over valued or under valued. Whether Adial Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Adial Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADIL.